Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer And Non-Small Cell Lung Cancer Patients Most Likely To Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows
For additional information, please visit Endocyte's website at www.endocyte.com .
Certain of the statements in this press release are forward looking, such as those, among others, relating to the potential effectiveness of folate receptor-targeted therapies and the ability to determine the folate receptor expression status of patients. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Stephanie Ascher Stern Investor Relations, Inc. (212) 362-1200 firstname.lastname@example.org Martina Schwarzkopf, Ph.D. Russo Partners (212) 845-4292 email@example.com Tony Russo, Ph.D. Russo Partners (212) 845-4251 firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts